Product Information

Janssen COVID-19 Vaccine - product monograph

Indication

  • Individuals 18 years of age and older 

Dose

  • 0.5 ml single dose given IM (preferably deltoid)
  • Note: There are no data available on the use of the Janssen COVID-19 Vaccine to complete a
    vaccination series initiated with another COVID-19 Vaccine.

Adverse Effects

Only short to medium term data are available at this time. Most adverse reactions occurred within 2 days following vaccination, were mild to moderate in severity, and of short duration (2 to 3 days). Surveillance will continue for long-term adverse effects.

The most commonly reported adverse effects included:  

  • injection site pain
  • headache
  • fatigue
  • myalgia
  • nausea

Drug Interactions

  • There are no known drug interactions. 

 

  • Under 18 years of age
    • The Janssen Covid-19 vaccine is approved for use in persons 18 years of age and older.
  • Previous severe allergic reaction after a dose of any other ‘adenovirus-based vaccine’
  • Reported hypersensitivity to one of the ingredients. See product monograph for ingredients. 
  • Other information will be added as it becomes available from NACI.
  • Currently feeling unwell with symptoms that could be COVID-19.
    • to avoid confusion if symptoms arise/worsen as they could be adverse effects of the vaccine or because of the underlying infection
    • to prevent potential transmission to others who are at the vaccine clinic/site (clients should be following public health quarantine recommendations)

Other information will be added as it becomes available from NACI.

Current Infection

  • Clients with current infection should not present for vaccination to prevent transmission to others at the vaccination clinic/site and should follow public health quarantine recommendations.

Past Infection

  • If acute symptoms have resolved and all quarantine orders have been followed, the client can be vaccinated.
    • However, the recommendation is for clients to wait 3 months to take advantage of the client's natural immunity and to leave the current supply of vaccine for others without immunity.
  • There is no information on the use of Janssen COVID-19 Vaccine with other vaccines at this time. 
  • Information will be updated based on NACI recommendations. 
  • There are no data available on the use of the Janssen COVID-19 Vaccine to complete a vaccination series initiated with another COVID-19 Vaccine.